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Natural Killer (NK) cells are large granular lymphocytes
that are uniquely equipped to promote the anti-tumor
response via communication with other immune cell
types in the tumor microenvironment. We have shown
that NK cells secrete a distinct profile of immune stimu-
latory factors e.g., interferon-gamma (IFN-g) with potent
anti-tumor activity in response to dual stimulation with
antibody (Ab)-coated tumor cells and cytokines, such as
interleukin (IL)-12 and that this response is significantly
enhanced 10 fold in the presence of autologous mono-
cytes (p < 0.05). Similar results were obtained when NK
cell secretion of TNF-alpha (a) and MIP1-a were exam-
ined. This enhancement of the NK cell cytokine response
by monocytes held true for every known stimulator of
NK cell IFN-g production. Further, autologous mono-
cytes significantly increased the ability of IL-12 activated
NK cells to lyse Trastuzumab-coated breast cancer cells
in an ADCC assay (p < 0.05). Monocyte enhancement of
NK cell activity was shown to be dependent on direct
cell-cell contact as determined by a transwell assay.
We hypothesized that NK cell effector functions against
Ab-coated tumor cells were enhanced via binding of the
stimulatory ligand MICA on monocytes to the NKG2D
receptor on NK cells. Activation of monocytes with bac-
terial components (e.g., LPS) or IFN-a led to increased
surface expression of the NKG2D ligand MICA and
further enhanced the ability of monocytes to act as sti-
mulators of NK cell cytokine secretion. The stimulatory
effects of MICA-positive monocytes were duplicated via
use of a MICA over-expressing cell line (C1R-MICA)
(inducing a 4 fold increase in IFN-g production) but not
the parental MICA-negative cell line. Down-modulation
of MICA via siRNA or incubation with a MICA neutra-
lizing FAb fragment prior to co-culture of monocytes
with NK cells led to a significant reduction in NK cell
IFN-g secretion (p < 0.05). Blockade of NKG2D on NK
cells with a neutralizing Ab also reduced IFN-g produc-
tion in this co-culture system. In vivo, depletion of mono-
cytes from Balb/c mice resulted in decreased IFN-g
production by murine NK cells upon exposure to Trastu-
zumab-coated tumor cells and IL-12. Extended depletion
of monocytes in vivo abrogated the immune response to
combination therapy with Trastuzumab and IL-12,
resulting in significantly larger tumors in monocyte-
depleted mice in comparison to mock-depleted controls
(p < 0.02). These data suggest that direct cell-cell interac-
tion between NK cells and monocytes may constitute
an important mechanism for enhancement of the NK
cell anti-tumor response in the setting of monoclonal
Ab therapy for cancer.
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